Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 27;22(9):666-674.
doi: 10.2174/1389203722666211109101853.

Peroxiredoxin-6: A Guardian of Lung Pathophysiologies

Anju Kumari  1 , Rimpy Kaur Chowhan  1 , Pushpa Kakchingtabam  2 , Sharifun Shahnaj  2 , Hamidur Rahaman  2 , Mohd Saquib Ansari  3 , Laishram Rajendrakumar Singh  1
Affiliations
Review

Peroxiredoxin-6: A Guardian of Lung Pathophysiologies

Anju Kumari et al. Curr Protein Pept Sci. .

Abstract

The moonlighting protein, Prdx-6, exhibits peroxidase activity, phospholipase activity, and lysophosphatidylcholine acyltransferase (LPCAT) activity. Although it is ubiquitous in expression, its level is prominently high in the lung. Prdx-6 has been known to be an important enzyme for the maintenance of normal lung physiologies including, anti-oxidant defense, lung surfactant homeostasis, and cell signaling. Studies further unveiled that the altered activity (peroxidase or ai- PLA2) of this enzyme is linked with various lung pathologies or diseases. In the present article, we attempted to address the various pathophysiologies or disease conditions (like lung ischemia, hyperoxia, lung cancer, emphysema, and acute lung injury) wherein Prdx-6 is involved. The study implicates that Prdx-6 could be used as a common drug target for multiple lung diseases. Important future insights have also been incorporated.

Keywords: Peroxiredoxin-6; acute lung injury; antioxidants; hyperoxia; pulmonary microvascular endothelial cells (PMVEC) .; reactive oxygen species (ROS).

PubMed Disclaimer